Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > Bad choice...

<< Previous

Bullboard Posts

Next >>

Comment by palinc2000on Mar 02, 2022 2:30pm

102 Views

Post# 34476030

RE:RE:Bad choice...

Closer to 3.50 cad

palinc2000 wrote: It sure seems that they did not anticipate the delay in determining the MTD and that they were expecting a rise in the SP if Phase 1 a results had been released in accordance to the original timeline,,,,The swoon as you call it is not quite as pronounced as you posted...The options were granted at 4.21 Cad and the current SP is 3.30 Cad...Still underwater but hopefully not for long

Wino115 wrote: Looks like CEO and Board should have waited for the option grants which normally would have happened right about now. All underwater by a chunk and likely some previously issued ones woudl be expiring around now. This swoon from $4 to $2.70 likely wiped out some decent money.

I actually would have much rather seen these become worth a nice bit of change for them all. Much more preferable to see their rewards aligned with shareholders and them doing well so that we all benefit and they taste the value of seeing the share build it's value and reflect what they're hard at work doing. As of now, all that work and not seeing any value. Let's hope that changes soon. We will be able to see whats out on the proxy and see what was given or exercised. Shame they didn't keep that momentum going through the trial.